12/5
07:00 am
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
08:43 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.
12/3
07:19 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
11/24
09:04 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) was given a new $41.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Viridian Therapeutics (NASDAQ:VRDN) was given a new $41.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/16
10:26 pm
vrdn
RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results [Yahoo! Finance]
Low
Report
RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results [Yahoo! Finance]
11/7
07:00 am
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/6
11:43 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Royal Bank Of Canada from $41.00 to $45.00. They now have an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Royal Bank Of Canada from $41.00 to $45.00. They now have an "outperform" rating on the stock.
11/6
10:12 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
11/5
07:36 am
vrdn
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress [Yahoo! Finance]
Low
Report
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress [Yahoo! Finance]
11/5
07:01 am
vrdn
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Medium
Report
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
11/4
08:09 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $61.00 price target on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $61.00 price target on the stock.
11/3
07:01 am
vrdn
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
Low
Report
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
10/21
11:24 pm
vrdn
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
Medium
Report
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
10/21
04:01 pm
vrdn
Viridian Therapeutics Announces Proposed Underwritten Public Offering
Medium
Report
Viridian Therapeutics Announces Proposed Underwritten Public Offering
10/21
09:57 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $32.00 to $36.00. They now have an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $32.00 to $36.00. They now have an "outperform" rating on the stock.
10/21
09:36 am
vrdn
Viridian Therapeutics (VRDN) Is Up 15.9% After $300 Million Royalty Deal to Fund Thyroid Eye Drug – Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Viridian Therapeutics (VRDN) Is Up 15.9% After $300 Million Royalty Deal to Fund Thyroid Eye Drug – Has The Bull Case Changed? [Yahoo! Finance]
10/20
07:30 am
vrdn
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
Low
Report
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
10/2
05:37 pm
vrdn
Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
Low
Report
Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
10/2
04:00 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/26
10:59 am
vrdn
Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease [Seeking Alpha]
Low
Report
Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease [Seeking Alpha]
9/15
07:14 am
vrdn
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates [Yahoo! Finance]
9/15
07:01 am
vrdn
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
Medium
Report
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates